TrianglePemigatinib After Chemotherapy (NCT04659616)
Pemigatinib After Chemotherapy trial for Newly Diagnosed Acute Myeloid Leukemia (NCT04659616). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for newly diagnosed acute myeloid leukemia, in adults.
The idea: add pemigatinib after standard induction chemotherapy. Pemigatinib blocks FGFR, a receptor that may contribute to the growth of leukemia cells. Induction chemotherapy uses cytarabine and daunorubicin. Patients must agree to bone marrow samples before the standard seven plus three induction begins. Leukemia genetics can differ between patients.
This phase 1 study looks for the best dose, and plans 32 patients. At OHSU Knight Cancer Institute in Portland, Oregon, Elie Traer leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.